Pharmaceuticals

Global Human Serum Albumin Industry Trends and Market Forecast 2026–2030

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the human serum albumin market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Human Serum Albumin Market’s size between 2026 and 2030?

The human serum albumin market size has seen robust expansion in recent years. It is anticipated to increase from $5.79 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical period’s growth can be linked to the limited availability of recombinant hsa, a reliance on plasma-derived hsa, increasing demand from hospitals and clinical settings, expanded application in diagnostic and therapeutic fields, and the adoption of standard injection solutions.

The human serum albumin market size is poised for robust expansion over the next few years, with projections indicating it will reach $8.16 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.0%. This anticipated growth is fueled by the development of yeast, bacterial, and plant-based recombinant hsa, an increasing need for fatty acid-free formulations, the widening application in drug delivery and nutrition enhancement, increased funding in research laboratories, and a rise in procurement from hospitals and blood banks. Significant trends during this forecast period include a surging demand for plasma-derived and recombinant human serum albumin, the increased utilization of hsa in volume expanders and drug delivery systems, a growing adoption of lyophilized powder and injection solutions, the expansion of its use in hospital and research laboratory environments, and an emphasis on fatty acid-free and specialized hsa preparations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Which Drivers Are Shaping Strategic Decisions In The Human Serum Albumin Market?

The escalating occurrence of liver ailments is projected to boost the expansion of the human serum albumin market in the future. These conditions encompass a range of disorders that hinder liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The rise in liver diseases stems from the growing incidence of obesity, where excessive abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), leading to fat accumulation, inflammation, and potential liver failure. Human serum albumin aids in managing liver disease by re-establishing blood volume, mitigating fluid retention, safeguarding kidney function, and enhancing results in complications like ascites and hepatorenal syndrome. A notable example occurred in December 2024, when a report from the Office for Health Improvement and Disparities, a UK government body, indicated a 3.6% increase in premature deaths from alcoholic liver disease in 2023, totaling 5,984 cases, up from 5,776 in 2022. Consequently, the growing incidence of liver conditions is fueling the expansion of the human serum albumin market.

What Segment Categories Are Covered In The Human Serum Albumin Market?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

How Are New Market Trends Shaping The Landscape Of The Human Serum Albumin Market?

Leading companies within the human serum albumin market are concentrating on developing novel solutions, like animal-free recombinant excipients, to improve product safety, expand scalability, and ensure adherence to regulatory requirements in biomanufacturing. An animal-free recombinant excipient is an inactive, biologically engineered substance created through recombinant DNA technology, completely free of animal or human components, guaranteeing high purity and safety for pharmaceutical and biomanufacturing uses. For instance, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, introduced Optibumin 25, which is the inaugural recombinant 25% human serum albumin for closed-system biomanufacturing. This product is optimized for workflows in downstream processing, formulation, and cryopreservation, and is presently offered in 100 mL single-use bags. Its animal-origin-free and chemically defined composition ensures superior purity, consistency, and minimizes contamination risks. Being GMP-ready and scalable to commercial production volumes, it provides a stable, sterile solution that seamlessly integrates into various applications, including viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Which Key Market Players Are Investing In Expansion And Innovation Within The Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Which Regions Are Poised For Strategic Growth In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Human Serum Albumin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company

Wall Decor Market Report 2026

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Market Report 2026

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795